Liquidia (LQDA) Share-based Compensation (2020 - 2026)
Liquidia's (LQDA) quarterly Share-based Compensation came in at $9.2 million in Q1 2026, up 23.92% year-on-year from $7.4 million in Q1 2025, and up 27.91% quarter-over-quarter from $7.2 million in Q4 2025.
Liquidia (LQDA) Share-based Compensation (2020 - 2026) Analysis & Trends
Liquidia's Share-based Compensation history runs 7 years deep, the most recent figure standing at $9.2 million for Q1 2026.
- On a quarterly basis, Share-based Compensation rose 23.92% year-over-year to $9.2 million in Q1 2026; TTM through Mar 2026 was $31.3 million, a 43.88% increase from a year earlier, with the FY2025 full-year figure at $37.9 million, up 101.76% from the prior year.
- Share-based Compensation climbed to $9.2 million in Q1 2026 per LQDA's latest filing, from $7.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $9.2 million in Q1 2026 and bottomed at $4185.0 in Q1 2022.
- The 5-year median for Share-based Compensation is $4.4 million (2024), against an average of $4.3 million.
- Across the five-year window, Share-based Compensation slumped 52.46% in 2022 and jumped 60879.69% in 2023, its largest moves.
- Year by year, Share-based Compensation stood at $1.8 million in 2022, then jumped by 40.32% to $2.6 million in 2023, then jumped by 97.14% to $5.0 million in 2024, then jumped by 43.29% to $7.2 million in 2025, then gained by 27.91% to $9.2 million in 2026.
- Per Business Quant, the three latest LQDA Share-based Compensation figures stand at $9.2 million (Q1 2026), $7.2 million (Q4 2025), and $7.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 9.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.22 Mn |
| Mar 31, 2026 | 9.22 Mn |
| Dec 31, 2025 | 7.21 Mn |
| Dec 31, 2025 | 7.21 Mn |
| Sep 30, 2025 | 7.90 Mn |
| Sep 30, 2025 | 7.90 Mn |
| Jun 30, 2025 | 6.93 Mn |
| Jun 30, 2025 | 6.93 Mn |
| Mar 31, 2025 | 7.44 Mn |
| Mar 31, 2025 | 7.44 Mn |
| Dec 31, 2024 | 5.03 Mn |
| Dec 31, 2024 | 5.03 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Jun 30, 2024 | 4.37 Mn |
| Jun 30, 2024 | 4.37 Mn |
| Mar 31, 2024 | 4.52 Mn |
| Mar 31, 2024 | 4.52 Mn |
| Dec 31, 2023 | 2.55 Mn |
| Dec 31, 2023 | 2.55 Mn |